BridgeMD
New treatment option for Ascending Colon Cancer
Official title LIRRH Trial for the Right-sided Colon Cancer
ClinicalTrials.gov ID: NCT07207317
What this study is testing
- What it's testing
- The aim of this clinical trial is to compare the short- and long-term outcomes of laparoscopic ileocecal reconstruction right hemicolectomy (LIRRH) with those of traditional laparoscopic right hemicolectomy (TRH) for ascending and proximal transverse colon cancer.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age 18-75 years
- ASA physical status ≤ III
- Endoscopy and biopsy-proven colon adenocarcinoma
- Contrast-enhanced abdominal CT showing primary tumor located in the ascending colon or proximal transverse colon (proximal one-third)
- Pre-operative clinical stage: TanyNanyM0
You likely can't join if
- History of hypertensive crisis or hypertensive encephalopathy.
- Severe cardiopulmonary insufficiency or any other contraindication to surgery.
- Uncorrectable electrolyte disturbances (e.g., potassium, calcium, magnesium).
- Evidence of significant bleeding diathesis or high hemorrhagic risk:
- Prior intracranial or intraspinal hemorrhage.
- Tumor invading major vessels with obvious bleeding risk.
See the full eligibility criteria
- Age 18-75 years
- ASA physical status ≤ III
- Endoscopy and biopsy-proven colon adenocarcinoma
- Contrast-enhanced abdominal CT showing primary tumor located in the ascending colon or proximal transverse colon (proximal one-third)
- Pre-operative clinical stage: TanyNanyM0
- Able to understand the study protocol, willing to participate, and provide written informed consent
- History of hypertensive crisis or hypertensive encephalopathy.
- Severe cardiopulmonary insufficiency or any other contraindication to surgery.
- Uncorrectable electrolyte disturbances (e.g., potassium, calcium, magnesium).
- Evidence of significant bleeding diathesis or high hemorrhagic risk:
- Prior intracranial or intraspinal hemorrhage.
- Tumor invading major vessels with obvious bleeding risk.
- Thrombotic or embolic event within 6 months before study treatment, or significant vascular disease (e.g., surgical-repair aortic aneurysm).
- Clinically relevant hemoptysis or tumor bleeding of any cause within 1 month before screening.
- Therapeutic-dose anticoagulation within 2 weeks before study treatment (except low-molecular-weight heparin).
- Antiplatelet therapy within 10 days before study treatment (e.g., aspirin \> 325 mg/day, clopidogrel \> 75 mg/day, dipyridamole, ticlopidine, cilostazol).
- Active tuberculosis.
- Any active autoimmune disease or history of autoimmune disease with expected recurrence (including but not limited to SLE, RA, autoimmune hepatitis, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis...
- Pre-operative evidence of synchronous multiple primary colorectal cancers or other conditions requiring additional bowel resection.
- Pre-operative imaging or intra-operative findings showing:
- Tumor infiltration into adjacent organs requiring multi-visceral resection;
- Distant metastasis;
- Unresectable (unable to achieve R0) disease.
- Other malignancies within the past 5 years, or familial adenomatous polyposis; except cured carcinoma in situ of the cervix, basal-cell carcinoma, papillary thyroid carcinoma, or cutaneous squamous-cell carcinoma.
- Intestinal obstruction, perforation, or bleeding requiring emergency surgery.
- Patient unsuitable or unable to tolerate laparoscopic surgery.
- Pregnant or lactating women.
- History of psychiatric disorders precluding compliance.
- Prior neoadjuvant therapy.
- Multidisciplinary team (MDT) decision that the patient is not appropriate for the study.
- Patient unable to understand the study conditions/objectives and refuses to give informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Shijiazhuang, Hebei, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shijiazhuang, Hebei, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.